Amgen Inc (AMGN)
Nasdaq · Common stock · Biological Products, (no Diagnostic Substances)
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow AMGN in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on AMGN and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
AMGN at a glance
Key statistics
$237.31B
Market capitalization
- Previous close
- $438.94
- Open
- $440.58
- Day range
- $434.62 – $440.91
- Volume
- 834.6K
- Average volume (30 sessions)
- 2.99M
- Shares outstanding
- 540.63M
- Price / earnings
- 27.1
- Earnings per share
- $16.17
- Price / book
- 20.3
- Price / sales
- 6.2
- Dividend yield
- 2.23%
- Beta (1 year, vs SPY)
- 0.47
Where the price sits in its year
52-week range
94% of the range
- Below the 52-week high
- -2.2%
- Above the 52-week low
- +51.8%
Completed sessions through Oct 20, 2026
Technical snapshot
Above its 50-day and 200-day averages
- 20-day average
- $416.41+5.4%
- 50-day average
- $415.73+5.6%
- 200-day average
- $369.94+18.7%
Between the conventional 30 and 70 bands.
+6.3%
1 week
+11.6%
1 month
+19.9%
3 months
+34.1%
Year to date
+46.9%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with AMGN
AMGN on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on AMGN.
See the plans →
Every planScreen names like AMGN
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on AMGN
Put AMGN on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on AMGN
See whether there is an open premium alert on AMGN, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
AMGN headlines
No headlines on the wire for AMGN in recent weeks.
SEC Form 4, most recent first
Insider filings
Khosla Rachna
−1.3K
SVP, Business Development · Open-market sale
$521.36K · Aug 13, 2026
Khosla Rachna
−2.0K
SVP, Business Development · Open-market sale
$825.13K · Aug 11, 2026
Khosla Rachna
+1.3K
SVP, Business Development · Option exercise
$203.58K · Aug 13, 2026
Khosla Rachna
−1.3K
SVP, Business Development · Option exercise
· Aug 13, 2026
Busch Matthew C.
+730
VP, Finance & CAO · Grant or award
· Aug 7, 2026
HOLLEY CHARLES M
+103.419
Director · Grant or award
· Aug 7, 2026
ISHRAK OMAR
+85.169
Director · Grant or award
· Aug 7, 2026
Drake Michael V
+63.876
Director · Grant or award
· Aug 7, 2026
About Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Biological Products, (no Diagnostic Substances)
- Headquarters
- Thousand Oaks, CA
- Employees
- 31,500
- Listed since
- Jun 17, 1983
- Website
- amgen.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.